TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones
Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted within the next six months
TG retains strategic flexibility with an option to buy back all rights under this agreement if TG is acquired
Conference call to be held today, August 1, 2023 at 8:30 AM ET/13:30 PM BST
